Mid
A
AVBPAI Stock Diagnostic Report
ArriVent plunges as lead asset fails in late-stage cancer trial
ArriVent BioPharma's lead candidate failed in a late-stage clinical trial, causing its stock price to plummet by more than 50%.
View Source Article ↗AI CATALYST SCORE50 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
AVBP Analysis History (Last 30 Days)